|
1
|
GLOBOCAN: The Global Cancer Observatory.
https://gco.iarc.fr/. Accessed July 1, 2020.
|
|
2
|
Znaor A, Lortet-Tieulent J, Laversanne M,
Jemal A and Bray F: International variations and trends in renal
cell carcinoma incidence and mortality. Eur Urol. 67:519–530.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Jemal A, Clegg LX, Ward E, Ries LA, Wu X,
Jamison PM, Wingo PA, Howe HL, Anderson RN and Edwards BK: Annual
report to the nation on the status of cancer, 1975-2001, with a
special feature regarding survival. Cancer. 101:3–27.
2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Low G, Huang G, Fu W, Moloo Z and Girgis
S: Review of renal cell carcinoma and its common subtypes in
radiology. World J Radiol. 8:484–500. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Salmond JM: Pathology of tumours of the
kidney and urinary tract. Surgery (Oxford). 37:481–486. 2019.
|
|
7
|
Escudier B, Porta C, Schmidinger M,
Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S and
Horwich A: ESMO Guidelines Committee. Renal cell carcinoma: ESMO
Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 30:706–720. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chandra A, Copen CE and Stephen EH:
Infertility and impaired fecundity in the United States, 1982-2010:
Data from the National Survey of Family Growth. Natl Health Stat
Report 1-18, 2013.
|
|
9
|
Chandra A, Copen CE and Stephen EH:
Infertility service use in the United States: Data from the
National Survey of Family Growth, 1982-2010. Natl Health Stat Rep
1-21, 2014.
|
|
10
|
Quaas AM and Legro RS: Pharmacology of
medications used for ovarian stimulation. Best Pract Res Clin
Endocrinol Metab. 33:21–33. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gibreel A and Bhattacharya S: Recombinant
follitropin alfa/lutropin alfa in fertility treatment. Biologics.
4:5–17. 2010.PubMed/NCBI
|
|
12
|
Tarlatzis BC, Zepiridis L, Grimbizis G and
Bontis J: Clinical management of low ovarian response to
stimulation for IVF: A systematic review. Hum Reprod Update.
9:61–76. 2003.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Check JH, Wilson C, Cohen R, Choe JK and
Corley D: Mid-luteal phase injection of subcutaneous leuprolide
acetate improves live delivered pregnancy and implantation rates in
younger women undergoing in vitro fertilization-embryo transfer
(IVF-ET). Clin Exp Obstet Gynecol. 42:427–428. 2015.PubMed/NCBI
|
|
14
|
Eftekhar M, Bagheri RB, Neghab N and
Hosseinisadat R: Evaluation of pretreatment with Cetrotide in an
antagonist protocol for patients with PCOS undergoing IVF/ICSI
cycles: A randomized clinical trial. JBRA Assist Reprod.
22:238–243. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Serour GI, Aboulghar M, Mansour R, Sattar
MA, Amin Y and Aboulghar H: Complications of medically assisted
conception in 3,500 cycles. Fertil Steril. 70:638–642.
1998.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li LL, Zhou J, Qian XJ and Chen YD:
Meta-analysis on the possible association between in vitro
fertilization and cancer risk. Int J Gynecol Cancer. 23:16–24.
2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rizzuto I, Behrens RF and Smith LA: Risk
of ovarian cancer in women treated with ovarian stimulating drugs
for infertility. Cochrane Database Syst Rev.
6(CD008215)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Dor J, Lerner-Geva L, Rabinovici J,
Chetrit A, Levran D, Lunenfeld B, Mashiach S and Modan B: Cancer
incidence in a cohort of infertile women who underwent in vitro
fertilization. Fertil Steril. 77:324–327. 2002.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Brinton LA, Scoccia B, Moghissi KS,
Westhoff CL, Althuis MD, Mabie JE and Lamb EJ: Breast cancer risk
associated with ovulation-stimulating drugs. Hum Reprod.
19:2005–2013. 2004.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gauthier E, Paoletti X and Clavel-Chapelon
F: E3N group. Breast cancer risk associated with being treated for
infertility: Results from the French E3N cohort study. Hum Reprod.
19:2216–2221. 2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Czarnecka AM, Niedzwiedzka M, Porta C and
Szczylik C: Hormone signaling pathways as treatment targets in
renal cell cancer (Review). Int J Oncol. 48:2221–2235.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Concolino G, Marocchi A, Conti C, Tenaglia
R, Di Silverio F and Bracci U: Human renal cell carcinoma as a
hormone-dependent tumor. Cancer Res. 38:4340–4344. 1978.PubMed/NCBI
|
|
23
|
Zucchetto A, Talamini R, Dal Maso L, Negri
E, Polesel J, Ramazzotti V, Montella M, Canzonieri V, Serraino D,
La Vecchia C and Franceschi S: Reproductive, menstrual, and other
hormone-related factors and risk of renal cell cancer. Int J
Cancer. 123:2213–2216. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bennett NC, Rajandram R, Ng KL and Gobe
GC: Evaluation of steroid hormones and their receptors in
development and progression of renal cell carcinoma. J Kidney
Cancer VHL. 1:17–25. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Keller G, Schally AV, Gaiser T, Nagy A,
Baker B, Halmos G and Engel JB: Receptors for luteinizing hormone
releasing hormone expressed on human renal cell carcinomas can be
used for targeted chemotherapy with cytotoxic luteinizing hormone
releasing hormone analogues. Clin Cancer Res. 11:5549–5557.
2005.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Radu A, Pichon C, Camparo P, Antoine M,
Allory Y, Couvelard A, Fromont G, Hai MT and Ghinea N: Expression
of follicle-stimulating hormone receptor in tumor blood vessels. N
Engl J Med. 363:1621–1630. 2010.
|
|
27
|
Siraj A, Desestret V, Antoine M, Fromont
G, Huerre M, Sanson M, Camparo P, Pichon C, Planeix F, Gonin J, et
al: Expression of follicle-stimulating hormone receptor by the
vascular endothelium in tumor metastases. BMC Cancer.
13(246)2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Siraj MA, Pichon C, Radu A and Ghinea N:
Endothelial follicle stimulating hormone receptor in primary kidney
cancer correlates with subsequent response to sunitinib. J Cell Mol
Med. 16:2010–2016. 2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Paterni I, Granchi C, Katzenellenbogen JA
and Minutolo F: Estrogen receptors alpha (ERα) and beta (ERβ):
Subtype-selective ligands and clinical potential. Steroids.
90:13–29. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lee HR, Kim TH and Choi KC: Functions and
physiological roles of two types of estrogen receptors, ERα and
ERβ, identified by estrogen receptor knockout mouse. Lab Anim Res.
28:71–76. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kouzu-Fujita M, Mezaki Y, Sawatsubashi S,
Matsumoto T, Yamaoka I, Yano T, Taketani Y, Kitagawa H and Kato S:
Coactivation of estrogen receptor β by gonadotropin-induced
cofactor GIOT-4. Mol Cell Biol. 34(919)2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen J, An BS, Cheng L, Hammond GL and
Leung PC: Gonadotropin-releasing hormone-mediated phosphorylation
of estrogen receptor-alpha contributes to fosB expression in mouse
gonadotrophs. Endocrinology. 150:4583–4593. 2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Speirs V, Skliris GP, Burdall SE and
Carder PJ: Distinct expression patterns of ER alpha and ER beta in
normal human mammary gland. J Clin Pathol. 55:371–374.
2002.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen GG, Zeng Q and Tse GM: Estrogen and
its receptors in cancer. Med Res Rev. 28:954–974. 2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Thomas C and Gustafsson JÅ: The different
roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer.
11:597–608. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
36
|
El-Deek HE, Ahmed AM, Hassan TS and Morsy
AM: Expression and localization of estrogen receptors in human
renal cell carcinoma and their clinical significance. Int J Clin
Exp Pathol. 11:3176–3185. 2018.PubMed/NCBI
|
|
37
|
Wang Q, Zhang W, Yang J, Liu YL, Yan ZX,
Guo ZJ, Li YJ and Bian XW: High ERα36 expression level and membrane
location predict poor prognosis in renal cell carcinoma. Medicine
(Baltimore). 94(e1048)2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ding J, Yeh CR, Sun Y, Lin C, Chou J, Ou
Z, Chang C, Qi J and Yeh S: Estrogen receptor β promotes renal cell
carcinoma progression via regulating LncRNA
HOTAIR-miR-138/200c/204/217 associated CeRNA network. Oncogene.
37:5037–5053. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Pan Y, Wu Y, Hu J, Shan Y, Ma J, Ma H, Qi
X and Jia L: Long noncoding RNA HOTAIR promotes renal cell
carcinoma malignancy through alpha-2, 8-sialyltransferase 4 by
sponging microRNA-124. Cell Prolif. 51(e12507)2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hong Q, Li O, Zheng W, Xiao WZ, Zhang L,
Wu D, Cai GY, He JC and Chen XM: LncRNA HOTAIR regulates HIF-1α/AXL
signaling through inhibition of miR-217 in renal cell carcinoma.
Cell Death Dis. 8(e2772)2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Pircher A, Wolf D, Heidenreich A, Hilbe W,
Pichler R and Heidegger I: Synergies of targeting tumor
angiogenesis and immune checkpoints in non-small cell lung cancer
and renal cell cancer: From basic concepts to clinical reality. Int
J Mol Sci. 18(2291)2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Song W, He D, Chen Y, Yeh CR, Hsu I, Huang
Q, Zhang X, Chang LS, Zuo L, Chen J, et al: Targeting newly
identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved
anti-estrogen Faslodex or an ERβ selective antagonist in renal cell
carcinoma. Mol Oncol. 12:2055–2071. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Gu J, Zhang Y, Han Z, Gao L, Cui J, Sun Y,
Niu Y, You B, Huang CP, Chang C, et al: Targeting the
ERβ/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the
FDA-approved anti-estrogen Faslodex to increase the Sunitinib
sensitivity in RCC. Cell Death Dis. 11(367)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Chevinsky M, Imnadze M, Sankin A, Winer A,
Mano R, Jakubowski C, Mashni J, Sjoberg DD, Chen YB, Tickoo SK, et
al: Pathological stage T3a significantly increases disease
recurrence across all tumor sizes in renal cell carcinoma. J Urol.
194:310–315. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Foersch S, Schindeldecker M, Keith M,
Tagscherer KE, Fernandez A, Stenzel PJ, Pahernik S, Hohenfellner M,
Schirmacher P, Roth W and Macher-Goeppinger S: Prognostic relevance
of androgen receptor expression in renal cell carcinomas.
Oncotarget. 8:78545–78555. 2017.PubMed/NCBI View Article : Google Scholar
|
